Proqr Therapeutics B.V. IPO Advisory
Share this IPO Profile:
Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
Proqr Therapeutics B.V. | PRQR - NASDAQ |
$11.00-$13.00 |
$13.00 |
$19.90 | 7.5 million | 9/18/2014 |
Leerink Partners, Deutsche Bank Securities |
Co-Manager(s): JMP Securities, H.C. Wainwright & Co. |
Health Care |
Filing(s): Filed 2014-08-13 Terms Added 2014-09-08
|
For IPO Boutique's "scale of 1 to 5" BUY rating on Proqr Therapeutics B.V., and our comprehensive analysis, click "Buy Market Research".
Proqr Therapeutics B.V. Quote & Chart - Click for current quote -
PRQR
About Proqr Therapeutics B.V. (adapted from Proqr Therapeutics B.V. prospectus):
They are an innovative biopharmaceutical company engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis, or CF. Utilizing our unique, proprietary RNA repair technologies, we believe we will be able to treat genetic disorders in which a single protein is defective due to certain types of genetic mutation.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "PRQR" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
© 2005 - 2024 IPO Boutique. All Rights Reserved